What is the optimal management of uterine adenosarcoma, including recommended surgical approach, criteria for fertility‑preserving surgery, indications for adjuvant radiation or chemotherapy, and recommended follow‑up schedule?

Uterine Adenosarcoma Management

Primary Surgical Treatment

Total abdominal hysterectomy with bilateral salpingo-oophorectomy is the standard surgical approach for uterine adenosarcoma, and routine lymphadenectomy is not indicated because lymph node metastasis occurs in less than 5% of cases. 1, 2

• The surgical procedure should achieve en bloc resection without tumor spillage, as morcellation significantly worsens prognosis if malignancy is confirmed postoperatively 1
• Minimally invasive approaches (laparoscopic or robotic) are acceptable provided the tumor is resected intact with the same oncologic principles as open surgery 1
• Peritoneal washings and thorough abdominal exploration should be performed at the start of surgery 1
• Lymphadenectomy adds no survival benefit and should be omitted unless there is macroscopic nodal involvement 1, 2

Fertility-Sparing Surgery

Fertility-sparing surgery is not supported by evidence and should not be considered standard of care for uterine adenosarcoma. 1

• This approach may be discussed with fully informed young patients who understand the increased risk of recurrence and death 1
• No established criteria exist for safe fertility preservation in adenosarcoma 1

Risk Stratification Based on Pathologic Features

The presence of sarcomatous overgrowth (>25% of tumor volume) is the single most important prognostic factor and fundamentally changes management:

Low-Risk Disease (No Sarcomatous Overgrowth)

• Stage I disease without sarcomatous overgrowth has a 22% recurrence rate 3
• 5-year overall survival is 60-80% in this group 2
• Observation alone is appropriate after complete surgical resection 2, 4

High-Risk Disease (Sarcomatous Overgrowth Present)

• Sarcomatous overgrowth increases recurrence risk to 77% even in stage I disease 2, 3
• 5-year overall survival drops to 50-60% with sarcomatous overgrowth 2, 3
• Median progression-free survival is only 29.4 months versus 105.9 months without overgrowth 3
• Additional adverse factors include myometrial invasion, lymphovascular space invasion, necrosis, and heterologous elements 2, 4, 3

Adjuvant Therapy Recommendations

Adjuvant Chemotherapy

For adenosarcoma with sarcomatous overgrowth (>25% of tumor volume), systemic chemotherapy following the uterine leiomyosarcoma paradigm is recommended. 1, 5

• Gemcitabine-docetaxel followed by doxorubicin is a supported regimen 1, 5
• Trabectedin has evidence supporting its use in high-grade uterine sarcomas including adenosarcoma with sarcomatous overgrowth 1, 5
• Doxorubicin, dacarbazine, and pazopanib are active agents that may be used sequentially 1
• For stage I disease with sarcomatous overgrowth, adjuvant chemotherapy appears to prolong progression-free survival (46.7 vs 29.4 months) and overall survival (97.3 vs 55.4 months), though these differences did not reach statistical significance in retrospective series 3
• No role exists for routine adjuvant chemotherapy in adenosarcoma without sarcomatous overgrowth 2, 4

Adjuvant Radiation Therapy

Adjuvant pelvic radiotherapy has not been shown to improve survival in uterine adenosarcoma and is not routinely indicated. 1, 5, 2

• Radiation therapy may be considered in highly selected cases with sarcomatous overgrowth, cervical involvement, parametrial involvement, or serosal involvement after multidisciplinary discussion 1, 5
• Retrospective data do not support routine use of pelvic radiotherapy as no survival benefit has been demonstrated 2
• The decision to use radiation should be made on a case-by-case basis weighing local recurrence risk against lack of proven survival benefit 1, 5

Management of Advanced or Metastatic Disease

Predominantly Epithelial Component

• Endocrine therapy may be considered if the tumor has a predominantly epithelial component 1, 6

Sarcomatous Overgrowth or High-Grade Features

• Treatment should follow protocols for high-grade uterine sarcomas using doxorubicin-based regimens, gemcitabine-docetaxel, trabectedin, or pazopanib in stepwise fashion 1, 5
• Surgical resection of isolated metastases should be considered when technically feasible 5

Follow-Up Schedule

High-risk adenosarcoma patients (those with sarcomatous overgrowth, myometrial invasion, or lymphovascular invasion) should be followed every 3-4 months for the first 2-3 years, then every 6 months through year 5, and annually thereafter. 5, 6

• Regular chest imaging is essential to detect pulmonary metastases, which are common in high-grade sarcomas 5, 6
• Low-risk patients (stage I without adverse features) may be followed every 3-6 months for 2 years, then every 6 months or annually 1
• Imaging should be performed as clinically indicated based on symptoms or examination findings 1

Critical Pitfalls to Avoid

• Do not perform morcellation of any uterine mass without definitive preoperative diagnosis, as tumor spillage dramatically worsens prognosis if adenosarcoma is present 1
• Do not omit bilateral salpingo-oophorectomy in premenopausal women based on the misconception that adenosarcoma is hormone-sensitive; the added value of oophorectomy is not established but is standard practice 1
• Do not assume adenosarcoma is an indolent tumor—at least 50% of patients develop recurrence, and those with sarcomatous overgrowth have aggressive disease requiring systemic therapy 4, 3
• Do not routinely use adjuvant radiation without high-risk features, as it has not improved survival in any prospective trial 1, 2
• Do not treat adenosarcoma with sarcomatous overgrowth the same as low-grade adenosarcoma—these are biologically distinct entities requiring chemotherapy 1, 5, 3